Quantcast

Latest Rivaroxaban Stories

2014-06-26 23:02:52

The firm currently represents patients who allege that they have suffered serious side effects from use of Xarelto. Rockville Centre, NY (PRWEB) June 26, 2014 The Rottenstein Law Group LLP, a national personal injury law firm that represents clients with claims stemming from injuries allegedly caused by dangerous prescription drugs, notes an increase in the number of adverse event reports involving the anticoagulant drug Xarelto® over other similarly prescribed drugs. “We are...

2014-06-25 23:11:26

Several Xarelto users are considering filing a Xarelto lawsuit after suffering dangerous side effects associated with the popular blood thinner drug Xarelto (rivaroxaban). The Levin, Papantonio law firm has launched a Xarelto lawsuit website to assist those who have been injured from severe internal bleeding experienced after taking the blood thinner drug. Pensacola, FL (PRWEB) June 25, 2014 Users of the prescription drug Xarelto (rivaroxaban) are beginning to file Xarelto lawsuits after...

2014-06-10 12:29:47

Additional Novel Oral Anticoagulants are Expected to Gain Approval in China for AF and VTE in the Next Three to Four Years, According to Findings from Decision Resources Group BURLINGTON, Mass., June 10, 2014 /PRNewswire/ -- Decision Resources Group finds that the high cost of therapy remains a significant barrier for uptake of novel oral anticoagulants (NOACs) in the Chinese market. Warfarin, the mainstay of anticoagulation treatment, is listed in the national essential drugs list and is...

2014-05-14 23:14:48

The DrugNews Center is the web’s largest source for prescription drug warnings, research and legal news. Visit http://www.DrugNews.net today. Chicago, IL (PRWEB) May 14, 2014 The drug safety advocates at DrugNews.net are alerting patients who have taken the anticoagulant Xarelto of new information on the site. A new report warns that the number of internal bleeding cases linked to the drug is steadily rising*. DrugNews is a free resource providing the latest product recalls, safety...

2014-04-17 12:27:18

Surveyed MCOs Indicate That Tier Position of Pradaxa and Eliquis Unlikely to Change Even With Addition of VTE Treatment to Label, According to Findings from Decision Resources Group BURLINGTON, Mass., April 17, 2014 /PRNewswire/ -- Decision Resources Group finds that the novel oral anticoagulants (NOACs) will dramatically alter the treatment landscape for VTE treatment and secondary prophylaxis. Surveyed emergency room physicians and cardiologists indicate that they currently use...

2014-03-31 08:29:45

RARITAN, N.J., March 31, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today it is adding three new clinical trials to its EXPLORER global cardiovascular research program for XARELTO(®) (rivaroxaban), the most studied and broadly indicated oral Factor Xa inhibitor in the world today. The additional trials will evaluate rivaroxaban for the treatment or prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in pediatric and other patient...

2014-03-03 23:02:09

Despite the FDA's recent rejection of Xarelto, Dr. Henry Mentz and the Aesthetic Center for Plastic Surgery plan to continue research. Houston, TX (PRWEB) March 03, 2014 Last month, the FDA denied approval of new uses for Johnson & Johnson’s blood thinning drug Xarelto. Dr. Mentz, of the Aesthetic Center for Plastic Surgery, will still continue his research on the drug, however. Xarelto was seeking clearance to treat patients with acute coronary syndrome (ACS) when it was...

2014-02-14 08:26:09

RARITAN, N.J., Feb. 14, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today the U.S. Food and Drug Administration (FDA) issued complete response letters (CRLs) regarding supplemental New Drug Applications (sNDAs) for the use of XARELTO(®) (rivaroxaban), an oral anticoagulant, to reduce the risk of secondary cardiovascular events - defined as heart attack, stroke or death - in patients with acute coronary syndrome (ACS) and to reduce the risk of stent...

2014-02-04 20:22:49

DUBLIN, February 5, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/vgwhc9/new_oral) has announced the addition of the "Concise Analysis of the International New Oral Anticoagulants Markets" [http://www.researchandmarkets.com/research/vgwhc9/new_oral ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Anticoagulants decrease the ability of the blood to create harmful blood clots that can...

2014-01-16 16:24:28

RARITAN, N.J., Jan. 16, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee has voted against the approval of the use of XARELTO(®) (rivaroxaban), an oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in patients with Acute Coronary Syndrome (ACS) in combination with standard antiplatelet therapy. Janssen is seeking approval of...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.